Aberrant HGF/MET signaling pathway activation may occur as a consequence of protein overexpression, gene amplification or activating mutations, which is associated with the development and progression of many types of cancer, including lung, renal, gastrointestinal, thyroid, and breast cancers as well as glioblastoma among others6, 7. Here, MET is linked to cancer.